Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	169.26	166.66	156.24	147.79	130.46	114.61
Revenue Growth (YoY)	7.49%	6.67%	5.71%	13.29%	13.83%	8.58%
Cost of Revenue	64.39	63.57	62.66	64.85	61.43	28.75
Gross Profit	104.87	103.09	93.58	82.94	69.03	85.86
Selling, General & Admin	90.38	95.85	84.79	74.1	60.06	34.95
Research & Development	32.45	32.69	28.18	27.33	23.43	16.67
Other Operating Expenses	62.19	62.19	0	0	42.52	0
Operating Expenses	185.02	190.73	112.98	101.42	126.01	51.62
Operating Income	-80.15	-87.64	-19.4	-18.48	-56.99	34.25
Interest Expense / Income	-3.47	-2.31	-0.65	0.19	0.3	-1.87
Other Expense / Income	1.1	-	-	-21.1	-28.67	-
Pretax Income	-77.78	-85.33	-18.75	2.43	-28.62	36.12
Income Tax	-0.95	-2.66	-3.89	-1.71	-4.64	8.93
Net Income	-76.83	-82.67	-14.86	4.13	-23.98	27.19
Net Income Growth	-	-	-	-	-	45.25%
Shares Outstanding (Basic)	15	15	15	14	14	14
Shares Outstanding (Diluted)	15	15	15	15	14	14
Shares Change	0.31%	0.65%	-0.50%	2.90%	-1.06%	-2.14%
EPS (Basic)	-5.25	-5.64	-1.02	0.29	-1.69	1.93
EPS (Diluted)	-5.25	-5.64	-1.02	0.28	-1.69	1.89
EPS Growth	-	-	-	-	-	48.82%
Free Cash Flow	-4.14	-7.22	-3.08	3.25	11.44	34.18
Free Cash Flow Per Share	-0.28	-0.49	-0.21	0.23	0.80	2.42
Gross Margin	61.96%	61.85%	59.89%	56.12%	52.91%	74.92%
Operating Margin	-47.35%	-52.58%	-12.42%	-12.50%	-43.68%	29.88%
Profit Margin	-45.39%	-49.60%	-9.51%	2.80%	-18.38%	23.73%
Free Cash Flow Margin	-2.45%	-4.33%	-1.97%	2.20%	8.77%	29.82%
Effective Tax Rate	-	-	-	-70.33%	-	24.72%
EBITDA	-68	-71.19	-3.06	18.64	-14.86	41.42
EBITDA Margin	-40.17%	-42.72%	-1.96%	12.61%	-11.39%	36.14%
Depreciation & Amortization	13.25	16.45	16.34	16.03	13.47	7.17
EBIT	-81.25	-87.64	-19.4	2.62	-28.32	34.25
EBIT Margin	-48.00%	-52.58%	-12.42%	1.77%	-21.71%	29.88%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).